» Articles » PMID: 12880286

Cyclosporine Binds to the Neutral Lipid and Potentially Other Binding Sites of Lipid Transfer Protein I

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2003 Jul 26
PMID 12880286
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The objective of this study was to determine if cyclosporine (CSA) binds directly to the neutral lipid-binding site of lipid transfer protein I (LTP I).

Methods: This was accomplished by determining LTP I concentrations and cholesteryl esters (CE) and CSA radioactivity of eluted fast protein liquid chromatography (FPLC) fractions following an injection of different treatment groups (i.e., LTP I alone, 3H-CE liposomes alone, 3H-CSA liposomes alone, 3H-CE liposomes + LTP I, and 3H-CSA liposomes + LTP I) onto an FPLC column. Our hypothesis is that CSA will bind to the neutral lipid-binding site of LTP I because of its high solubility/interaction with cholesterol and triglycerides.

Results: Coincubation of LTP I with 3H-CE liposomes resulted in a significant decrease in the LTP I peak reported at fraction 10 and the appearance of a broad LTP I peak at fractions 30-34 compared to control. Coincubation of LTP I with 3H-CSA liposomes resulted in a significant decrease in the LTP I peak reported at fraction 10 and fraction 30 compared to control. In addition, 30% of the original radioactivity associated with 3H-CSA liposomes was found coeluted with the unbound LTP I peak at fraction 10. Taken together, these findings suggest that CSA does bind to the neutral lipid-binding site of LTP I but may also bind to other regions along the LTP I molecule.

Conclusions: We have determined that LTP I mediated transfer of CSA between lipoproteins may be a result of the direct binding of CSA to LTP I at both its neutral binding site and potentially other binding sites along the molecule. These findings provide further evidence that the distribution/redistribution of drugs among plasma lipoproteins facilitated by LTP I may serve as a possible mechanism for determining the ultimate fate of drug compounds.

References
1.
Albers J, Tollefson J, Chen C, Steinmetz A . Isolation and characterization of human plasma lipid transfer proteins. Arteriosclerosis. 1984; 4(1):49-58. DOI: 10.1161/01.atv.4.1.49. View

2.
Nemunaitis J, Deeg H, Yee G . High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridaemia. Lancet. 1986; 2(8509):744-5. DOI: 10.1016/s0140-6736(86)90254-0. View

3.
Glenn K, Melton M . Quantification of cholesteryl ester transfer protein: activity and immunochemical assay. Methods Enzymol. 1996; 263:339-51. DOI: 10.1016/s0076-6879(96)63026-2. View

4.
De Klippel N, Sennesael J, Lamote J, Ebinger G, De Keyser J . Cyclosporin leukoencephalopathy induced by intravenous lipid solution. Lancet. 1992; 339(8801):1114. DOI: 10.1016/0140-6736(92)90707-a. View

5.
MORTON R, ZILVERSMIT D . Purification and characterization of lipid transfer protein(s) from human lipoprotein-deficient plasma. J Lipid Res. 1982; 23(7):1058-67. View